Endometrial safety of ospemifene: results of the phase 2/3 clinical development program

OBJECTIVE: This study aims to assess the endometrial safety of ospemifene based on phase 2/3 clinical trials of postmenopausal women with up to 52 weeks of exposure to ospemifene 60 mg/day versus placebo. METHODS: Endometrial safety was evaluated in a development program of six randomized, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Constantine, Ginger D., Goldstein, Steven R., Archer, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott-Raven Publishers 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274342/
https://www.ncbi.nlm.nih.gov/pubmed/24977459
http://dx.doi.org/10.1097/GME.0000000000000275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274342/
https://www.ncbi.nlm.nih.gov/pubmed/24977459
http://dx.doi.org/10.1097/GME.0000000000000275

Ejemplares similares